Perioperative Morbidity and Mortality Associated With Bleomycin in Primary Mediastinal Nonseminomatous Germ Cell Tumor

2016 ◽  
Vol 34 (36) ◽  
pp. 4445-4446 ◽  
Author(s):  
Praveen Ranganath ◽  
Kenneth A. Kesler ◽  
Lawrence H. Einhorn
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Cell Tumor ◽  
Morbidity And Mortality ◽  
Perioperative Morbidity ◽  
Nonseminomatous Germ Cell Tumor

Perioperative morbidity and mortality with bleomycin in primary mediastinal non seminomatous germ cell tumor (PMNSGCT).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 4538-4538
Author(s):  
Praveen Ranganath ◽  
Kenneth Kesler ◽  
John Dentel ◽  
Lawrence H. Einhorn
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Cell Tumor ◽  
Morbidity And Mortality ◽  
Perioperative Morbidity

Cytogenetic analysis of the mature teratoma and the choriocarcinoma component of a testicular mixed nonseminomatous germ cell tumor

1992 ◽  
Vol 61 (1) ◽  
pp. 67-73 ◽  
Author(s):  
Willem E. de Graaff ◽  
J. Wolter Oosterhuis ◽  
Bauke de Jong ◽  
Jannie van Echten-Arends ◽  
Janneke Wiersema-Buist ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Cytogenetic Analysis ◽  
Mature Teratoma ◽  
Cell Tumor ◽  
Nonseminomatous Germ Cell Tumor

scholarly journals Secondary malignancies among nonseminomatous germ cell tumor cancer survivors

Cancer ◽  
2011 ◽  
Vol 117 (18) ◽  
pp. 4219-4230 ◽  
Author(s):  
Karim Chamie ◽  
Eric A. Kurzrock ◽  
Christopher P. Evans ◽  
Mark S. Litwin ◽  
Theresa M. Koppie ◽  
...  
Keyword(s):  
Cancer Survivors ◽  
Germ Cell ◽  
Germ Cell Tumor ◽  
Cell Tumor ◽  
Secondary Malignancies ◽  
Nonseminomatous Germ Cell Tumor

scholarly journals The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor

Cancer ◽  
2008 ◽  
Vol 112 (4) ◽  
pp. 800-805 ◽  
Author(s):  
Atreya Dash ◽  
Brett S. Carver ◽  
Jason Stasi ◽  
Dean F. Bajorin ◽  
Robert J. Motzer ◽  
...  
Keyword(s):  
Lymph Node ◽  
Germ Cell ◽  
Lymph Node Dissection ◽  
Germ Cell Tumor ◽  
Clinical Stage ◽  
Cell Tumor ◽  
Node Dissection ◽  
Nonseminomatous Germ Cell Tumor

Incidence of Metastatic Nonseminomatous Germ Cell Tumor Outside the Boundaries of a Modified Postchemotherapy Retroperitoneal Lymph Node Dissection

2007 ◽  
Vol 25 (28) ◽  
pp. 4365-4369 ◽  
Author(s):  
Brett S. Carver ◽  
Bobby Shayegan ◽  
Scott Eggener ◽  
Jason Stasi ◽  
Robert J. Motzer ◽  
...  
Keyword(s):  
Lymph Node ◽  
Germ Cell ◽  
Germ Cell Tumor ◽  
Testicular Tumor ◽  
Cell Tumor ◽  
Retroperitoneal Lymph Node Dissection ◽  
Retroperitoneal Lymph Node ◽  
Radiographic Evidence ◽  
Nonseminomatous Germ Cell Tumor ◽  
Institutional Review

Introduction Modified template retroperitoneal lymph node dissections (RPLND) have become increasing applied in the postchemotherapy (PC) setting. We evaluated our experience with PC-RPLND to determine the incidence of disease extending outside the boundaries of a modified PC-RPLND. Patients and Methods From 1989 through 2003, a total of 532 men underwent PC-RPLND for metastatic nonseminomatous germ cell tumor (NSGCT). Of these, 269 (51%) had either viable germ cell tumor (GCT) or teratoma present in the RPLND specimen. After Institutional Review Board approval, clinical and pathologic data were obtained from our prospective surgical database. The incidence of retroperitoneal disease outside the boundaries of five modified templates was reported for the presence of viable GCT or teratoma. Results Of the 269 patients with viable GCT or teratoma, 20 to 86 (7% to 32%) patients had evidence of extratemplate retroperitoneal disease, depending on the boundaries of the modified template. There was no difference in the histologic distribution for patients with disease confined to or outside of the modified templates. Despite the absence of preoperative radiographic evidence of disease outside the boundaries of the Testicular Tumor Study Group template, the incidence of extratemplate metastasis for men with residual retroperitoneal masses less than 1, 1 to 2, 2 to 5, and more than 5 cm was two of 24 (8%), seven of 38 (18%), 27 of 92 (29%), and 14 of 55 (25%), respectively. Conclusion Our data suggest a bilateral RPLND is a prudent approach for the management of men with metastatic NSGCT after chemotherapy, given that at least 7% to 32% of men will have teratoma or viable GCT outside the boundaries of a modified template.

Sign in / Sign up

Export Citation Format

Share Document